Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pivotal trial of ELX-02 for the treatment of Alport syndrome with nonsense mutations

Next Previous
Trial Profile

Pivotal trial of ELX-02 for the treatment of Alport syndrome with nonsense mutations

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 21 Aug 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Exaluren (Primary)
  • Indications Hereditary nephritis
  • Focus Registrational; Therapeutic Use
  • Sponsors Eloxx Pharmaceuticals

Most Recent Events

  • 12 Aug 2026 According to an Eloxx Pharmaceuticals media release, the trial is expected to initiate in the third quarter of 2026.
  • 11 Jul 2024 According to an Eloxx Pharmaceuticals media release, company received positive written FDA feedback and guidance from a pre-Investigational New Drug Application (PIND) meeting provides pathway to IND application submission to initiate this trial.
  • 16 Apr 2024 According to an Eloxx Pharmaceuticals media release, The company is looking forward to engaging the FDA on initiating the larger clinical trial to support the potential for regulatory marketing approval of ELX-02 in Alport syndrome with nonsense mutations patient.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top